Ascendis Pharma ADR had its Relative Strength (RS) Rating upgraded from 65 to 79 Monday — a welcome improvement, but still below the 80 or better score you look for.
IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves. See if Ascendis Pharma ADR can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Ascendis Pharma ADR is building a consolidation with a 161.00 buy point. See if it can break out in heavy volume.
Ascendis Pharma ADR posted 0% EPS growth last quarter. Revenue increased 184%.
Ascendis Pharma ADR earns the No. 147 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
